share_log

Lilly And Incyte Announce Results From The Phase 3 COV-BARRIER Study Of Baricitinib In Hospitalized Covid-19 Patients' The Co,'s Report 'The trial did not meet statistical significance on the prima

Lilly And Incyte Announce Results From The Phase 3 COV-BARRIER Study Of Baricitinib In Hospitalized Covid-19 Patients' The Co,'s Report 'The trial did not meet statistical significance on the prima

礼来公司和Incell公司宣布了巴利替尼在住院新冠肺炎患者中的3期COV屏障研究的结果，该试验在初始阶段没有统计学意义
Benzinga Real-time News ·  2021/04/08 18:46

Lilly And Incyte Announce Results From The Phase 3 COV-BARRIER Study Of Baricitinib In Hospitalized Covid-19 Patients' The Co,'s Report 'The trial did not meet statistical significance on the primary endpoint'

礼来公司和Incell公司公布了巴利替尼在住院新冠肺炎患者中的3期COV屏障研究结果，该公司的报告称，该试验没有达到主要终点的统计学意义。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发